SCHEMBL17049075

SCHEMBL17049075

O=C(O)c1ccc(CI)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
RARB P10826 3/20 0.46
RARA P10276 2/20 0.46
RARG P13631 1/20 0.46
RXRA P19793 3/20 0.44
RXRB P28702 2/20 0.43
RXRG P48443 2/20 0.43
KLKB1 P03952 1/20 0.41
CTSB P07858 1/20 0.41
MMP9 P14780 1/20 0.41
DNMT1 P26358 1/20 0.41
DNMT3B Q9UBC3 1/20 0.41
DNMT3L Q9UJW3 1/20 0.41
DNMT3A Q9Y6K1 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
ALDH1A1 P00352 1/20 0.40
CDC25B P30305 1/20 0.40
CASP6 P55212 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27830980 0.86 MRGPRX4 (0.50) RARBRARARARGKLKB1CTSB
SCHEMBL14728203 0.85 ALDH1A1 (0.47) EPHX2NR1H4RARBRARARARG
SCHEMBL542783 0.82 PRKAB2 (0.49) EPHX2NR1H4RARBRARARARG
SCHEMBL506187 0.80 EPHX2 (0.47) EPHX2NR1H4RARBRARARARG
SCHEMBL669282 0.80 RARB (0.54) EPHX2NR1H4RARBRARARARG
SCHEMBL2845325 0.80 EPHX2 (0.47) EPHX2NR1H4RARBRARARARG
SCHEMBL9856029 0.80 FOLH1 (0.54) EPHX2NR1H4RARBRARARARG
SCHEMBL28615500 0.80 KLKB1 (0.41) KLKB1CTSBMMP9DNMT1DNMT3B
SCHEMBL31490890 0.80 SRD5A2 (0.57) EPHX2NR1H4RARBRARARARG
SCHEMBL13746058 0.80 EPHX2 (0.47) EPHX2NR1H4RARBRARARARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10005741-B2 Therapeutic compounds ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-06-26 US disclosed
US-20180141921-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-05-24 US disclosed
US-9908856-B2 Therapeutic compounds ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-03-06 US disclosed
US-20170008859-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2017-01-12 US disclosed
WO-2015130973-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2015-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008859-A1 THERAPEUTIC COMPOUNDS IAPP, PARK7, NLN EPHX2 2575/4885NR1H4 2273/4885RARB 379/4885
US-20180141921-A1 THERAPEUTIC COMPOUNDS IAPP, PARK7, NLN EPHX2 2575/4885NR1H4 2273/4885RARB 379/4885
US-10005741-B2 Therapeutic compounds IAPP, PARK7, NLN EPHX2 2575/4885NR1H4 2273/4885RARB 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.